Walleye Capital
VRCA icon

Walleye Capital’s Verrica Pharmaceuticals VRCA Stock Holding History

Walleye Capital’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,240
Closed -$127K – 5035
2025
Q4 		$127K Buy
+15,240
New +$84.5K ﹤0.01% 3771

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's VRCA Position: Q1 2026 in Review

Walleye Capital sold out of Verrica Pharmaceuticals (VRCA) in Q1 2026, closing a stake of 15,240 shares — an estimated $127K sold.

Walleye Capital first reported a position in VRCA in Q4 2025 and held it in 1 quarter. The position peaked at $127K in Q4 2025. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Walleye Capital reported no remaining Verrica Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 15,240 Verrica Pharmaceuticals shares in Q1 2026, an estimated $127K.
  • Walleye Capital first reported a position in Verrica Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Walleye Capital's Verrica Pharmaceuticals position peaked at $127K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.